The plasma concentration of etomidate during the eSAM test

The plasma concentration of etomidate during the eSAM test and the meaning for clinic

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022895

Enrollment

Unknown

Registered

2019-04-30

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Case series:etomidate

Eligibility

Sex/Gender

All

Age

18 Years to 78 Years

Inclusion criteria

Inclusion criteria: The patients with intractable epilepsy who have preoperative assessment are performed eSAM tests in our hospital and accomplish both brain hemisphere tests smoothly.

Exclusion criteria

Exclusion criteria: During the test, the patients have seizures; With other sedatives or drugs which will effect the metabolism of etomidate; With liver or kidney dysfunction; With metabolic disease; Drug allergy, etc.

Design outcomes

Primary

Measure	Time frame
etomidate plasma concentration;	—

Secondary

Measure	Time frame
Video EEG monitoring;neuropsychological assessment scale;	—

Contacts

Public ContactCai Xiaodong

Functional Neurology Department of Shenzhen Second People's Hospital

13632660199@126.com+86 13632660199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026